Features March 2019 Issue

Warning: Common Pain Relievers Unsafe for Heart Patients

Warning: Common Pain Relievers Unsafe for Heart Patients

Fortunately, there are alternatives for those needing daily pain relief.

The FDA mandated a cardiovascular safety trial of celecoxib (Celebrex®). This trial, spearheaded by Dr. Nissen, compared moderate doses of celecoxib to ibuprofen and naproxenin 24,081 arthritis patients at increased cardiovascular risk needing daily pain relief. The cardiovascular risks from celecoxib were no greater than those conferred by the other NSAIDs.

To continue reading this article you must be a paid subscriber.

Subscribe to Heart Advisor

Get the next year of HEART ADVISOR for just $20. That's a savings of $19 off the regular rate.

With your paid subscription you will receive unlimited access to all of our online content. That is over a decade of previous issues from Cleveland Clinic, the hospital rated #1 in cardiac care by U.S. News & World Report - free of charge.

Subscriber Log In

Forgot your password? Click Here.

Already subscribe but haven't registered for all the benefits of the website? Click here.